CDX-014

N/A

Report date: 2024/02/05 13:57:29

Base Information

Drug NameCDX-014
Drug Alias NameCDX-014CR 014-vcMMAE
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsT-cell immunoglobulin mucin receptor 1 inhibitors
TargetsT-cell immunoglobulin mucin receptor 1Tubulin
Therapy Area/IndicationsKidney NeoplasmsOvarian NeoplasmsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCuragen CorporationAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelldex Therapeutics
Active IndicationsN/A
Inactive IndicationsKidney NeoplasmsOvarian NeoplasmsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A